Tesamorelin's HIV lipodystrophy evidence

Tesamorelin has exactly one approved indication anywhere in the world. The US label describes it as indicated for "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy"^[4]. Almost everything written about tesamorelin online concerns uses it was never licensed for. Two separate meta-analyses published in 2026 went back to the trials that earned the approval and pooled them. They broadly agree on what the drug does to fat. They part company on how worried to be about safety.

The July 2026 pooled analysis: four trials, 909 patients

The newer of the two appeared in the Journal of the International Association of Providers of AIDS Care and went online on 31 July 2026. Its authors searched PubMed, ClinicalTrials.gov and Scopus to 9 February 2026 and found four randomised controlled trials, covering 909 patients between them, of tesamorelin in HIV-associated lipodystrophy in people on combined antiretroviral therapy^[1]. Pooled, tesamorelin 2 mg reduced visceral adipose tissue by a mean difference of 21.47 against placebo (95% CI 8.22 to 34.73), with substantial disagreement between the trials on that endpoint (I2 of 74%). One caveat worth flagging: the published abstract reports that headline figure without a unit attached. The trials in this literature measure visceral fat by CT scan in square centimetres, and the second 2026 review reports its equivalent number that way^[2].

The body-composition results were tighter and far more consistent between trials. Waist circumference fell by 1.61 cm (95% CI 0.95 to 2.28) and trunk fat by 1.20 kg (95% CI 0.93 to 1.47), both with no measurable heterogeneity. Lean body mass rose by 1.42 kg (95% CI 1.13 to 1.71). Total cholesterol shifted by 0.16 mmol/L, which the authors themselves described as modest^[1]. These are real but small numbers, and the reader who arrives expecting a weight-loss drug in the mould of semaglutide is looking at the wrong kind of effect.

A second 2026 review, and where the two diverge

Six months earlier, Obesity Research and Clinical Practice published its own pooled analysis, this one covering five randomised controlled trials and adding hepatic fat to the outcome list^[2]. Its visceral-fat estimate was larger: a reduction of 27.71 cm squared (95% CI 17.06 to 38.37). Its lean-body-mass figure was identical to the later review's, at 1.42 kg. It found no significant change in subcutaneous fat or in BMI, which is the detail most often lost in community discussion. The drug moves visceral fat specifically. It does not move the number on the scale.

The two reviews land differently on safety, and that is the more interesting divergence. The Obesity Research and Clinical Practice authors concluded that tesamorelin improved body composition, hepatic fat, lean body mass and IGF-1 "without serious side effects or perturbation of glucose"^[2]. The July review reported growth-hormone-related adverse effects and a higher discontinuation rate, and closed by saying that limited data on long-term safety, optimal dosing strategies and durability of treatment effects "warrant caution"^[1]. Same drug, same population, overlapping trial sets, different framing. A reader who found only one of the two would walk away with a different sense of the risk. The signals themselves are on our tesamorelin safety section.

The discontinuation number, read properly

The July review put the discontinuation risk ratio at 2.25, with a 95% confidence interval running from 0.98 to 5.17 and a p-value of 0.06^[1]. That interval crosses 1, so the result did not reach statistical significance. It would be equally wrong to read it as "no difference". The point estimate is more than double, the lower bound sits within touching distance of 1, and the trials pooled here are not large enough to settle the question either way.

The prescribing information carries the specifics that a pooled ratio compresses. In the trials behind the US approval, 5% of tesamorelin-treated patients developed an HbA1c of 6.5% or above, against 1% on placebo, a hazard ratio of 3.3^[4]. Serum IGF-1 rises meaningfully: the 2007 New England Journal of Medicine trial in 412 patients recorded an 81.0% increase in IGF-1 on tesamorelin against a 5.0% fall on placebo^[3]. The label says plainly that the effects of prolonged elevations in IGF-1 are unknown, and it contraindicates the drug in active malignancy, in disruption of the hypothalamic-pituitary axis, in known hypersensitivity, and in pregnancy^[4].

Why this evidence does not travel to off-label use

Every patient in every trial pooled by either review had HIV and was taking antiretroviral therapy. That is the population the effect estimates describe, and it is the population the label describes^[4]. The growth-hormone-axis peptides most often discussed alongside tesamorelin, CJC-1295 and ipamorelin among them, have nothing resembling this trial base behind them, and neither does tesamorelin itself outside the licensed indication.

Whether the indication still matters on modern antiretroviral regimens is a live question rather than a closed one. A 2024 trial in 38 people with HIV on integrase-inhibitor regimens reported visceral fat falling over 12 months on tesamorelin while the placebo group gained visceral fat despite stable BMI^[6]. That is a small study, and it is not a licensing decision, but it argues against the assumption that HIV-associated lipodystrophy aged out along with the older drug classes that first caused it.

Where this lands

None of it changes the access picture outside the United States. Ferrer Internacional withdrew the European marketing-authorisation application on 21 June 2012, telling the CHMP that the data did not allow the committee to conclude on a positive benefit-risk balance. The committee had questioned whether clinicians could distinguish lipodystrophy fat from ordinary obesity, whether the fat reduction was clinically meaningful, and whether the trial population resembled European patients, and it had flagged the IGF-1 rise as a cancer and diabetic-eye-disease concern with no long-term safety data supplied^[5]. Two 2026 meta-analyses of those same trials do not answer any of that, because they are pooling evidence the CHMP already saw.

So the position is unchanged. There is a licensed product in the United States and nothing licensed in the United Kingdom, Germany or the Netherlands or Sweden, where lawful supply runs only through unlicensed-medicine or named-patient routes on a prescriber's responsibility. The country-by-country picture sits on the tesamorelin regulation section. What 2026 added is better arithmetic on an old dataset, not new grounds for anyone outside the licensed indication to act on. This article is educational and is not medical advice. Any decision about tesamorelin belongs with a clinician who knows your history.